Genetic News and Research

RSS

Symposium on genetics of psoriasis and psoriatic arthritis to be held

A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.

24 Sep 2009

Jean-Pol Tassin honored with the ECNP Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Jean-Pol Tassin as the recipient of the 2009 ECNP Neuropsychopharmacology Award in Basic Science Research in recognition of his pioneering and innovative research into the neurochemical basis of substance addiction.

24 Sep 2009

Research to identify inborn genetic susceptibility to colon cancer metastasis

A prestigious National Institutes of Health (NIH) Transformative R01 Program grant for $4.9 million has been awarded to Case Western Reserve University School of Medicine. The five-year grant will fund research to identify patients' inborn genetic susceptibility to the development of colon cancer metastasis. Case Western Reserve was one of only 42 recipients of this competitive new grant designed to support exceptionally innovative, high risk, original and/or unconventional research projects that have the potential to create or overturn fundamental paradigms.

24 Sep 2009

Scientist reveals that selecting optimal radiation dosage for a patient is possible

An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia

24 Sep 2009

Rescuing immune system cells can reduce risk of prostate cancer

Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.

24 Sep 2009

BREVAGen test offers precise breast cancer risk assessment

Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S. markets. Perlegen plans to add sales areas to make the test available nationwide over the next few months.

24 Sep 2009

TSPs can block cancer-triggering proto-oncogenes

A tiny bit of genetic material with no previously known function may hold the key to stopping the spread of cancer, researchers at Yale School of Medicine and Sichuan University in Chengdu, China report in two papers in the September 7-11 issue of Proceedings of the National Academy of Sciences.

24 Sep 2009

Genetic variation helps identify hepatitis C infected people, according to a study

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

24 Sep 2009

Interleukin Genetics reports positive results from clinical study on weight management

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association.

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

Winner of the 2009 ECNP Neuropsychopharmacology Award

23 Sep 2009

Agilent Technologies and Applied Biosystems to co-market SureSelect system

Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.

23 Sep 2009

Technological and scientific initiatives from Helicos BioSciences Corporation

Helicos BioSciences Corporation provided updates on recent scientific findings and progress on Helicos’s technology initiatives. Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the CHI Next Generation Sequencing conference in Providence, RI, Patrice Milos, Ph.D. Vice President and Chief Scientific Officer provided an overview of recent technological and scientific initiatives underway at Helicos.

23 Sep 2009

Advanced Hair Studio to introduce genetic baldness tests in Australia

Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC. (www.hairdx.com)

23 Sep 2009

Advancements in the treatment of metastatic malignant melanoma

23 Sep 2009

Celera and Medco collaborate in KIF6 gene variant testing

Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy. Current studies have suggested that only about 50 to 60 percent of the patients who receive a prescription for a lipid-lowering drug are taking the medication after six months.

23 Sep 2009

$Using moldable pastes to repair fractures in the future$

Using moldable pastes to repair fractures in the future

New stem cell studies at the University of Maryland Dental School demonstrate that surgeons could one day routinely use strong, moldable, and injectable pastes to regenerate needed bone tissue to repair broken bones, fractures, genetic defects, even combat bone wounds.

23 Sep 2009

Researching the causes of Alzheimer's disease

The standard explanation for what causes Alzheimer's is known as the amyloid hypothesis, which posits that the disease results from of an accumulation of the peptide amyloid beta, the toxic protein fragments that deposit in the brain and become the sticky plaques that have defined Alzheimer's for more than 100 years.

23 Sep 2009